HFA 23: REDWOOD-HCM-Cohort 4: Aficamten in Non-obstructive Hypertrophic Cardiomyopathy

We are joined by Dr Ahmad Masri (Oregon Health & Science University Medical Group, US) to discuss the findings from REDWOOD-HCM cohort 4. REDWOOD-HCM Cohort 4 assessed the safety and tolerability of the selective inhibitor of cardiac myosin, aficamten in patients with symptomatic nHCM. Cohort 4 included 41 patients. The data presented at HFA 23 shows that aficamten treatment was well-tolerated in patients with nHCM, supporting further study of the drug in a phase 3 trial. Interview Questions: -What is currently understood about the pathophysiology of nHCM and what treatment options are available in 2023? -How does Aficamten, a selective inhibitor of cardiac myosin, work? -What was the study design, patient population, and outcome measures of REDWOOD-HCM-Cohort 4? -What data was presented at the HFA and what conclusions can be drawn from the findings? -What safety considerations and adverse events were observed? -What are the next steps in research or clinical development? Visit Radcliffe Cardiology: https://www.radcliffecardiology.com/?... This content is intended for healthcare professionals only. Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster. Like us on Facebook:   / radcliffecardiology   Follow us on Twitter:   / radcliffecardio